<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40865109</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2590-7379</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>Biomedica : revista del Instituto Nacional de Salud</Title><ISOAbbreviation>Biomedica</ISOAbbreviation></Journal><ArticleTitle>Prevalence and characterization of human immunodeficiency virus coinfection in patients hospitalized with tuberculosis in a reference hospital in Bogot&#xe1;.</ArticleTitle><Pagination><StartPage>423</StartPage><EndPage>435</EndPage><MedlinePgn>423-435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7705/biomedica.7664</ELocationID><Abstract><AbstractText>Introducci&#xf3;n. La tuberculosis es la principal causa de muerte en los pacientes con infecci&#xf3;n por el virus de la inmunodeficiencia humana. La coinfecci&#xf3;n de Mycobacterium tuberculosis y HIV es muy frecuente. Objetivo. Establecer la prevalencia de la infecci&#xf3;n por HIV en pacientes hospitalizados con tuberculosis, y determinar sus caracter&#xed;sticas y desenlaces. Materiales y m&#xe9;todos. Se realiz&#xf3; un estudio retrospectivo, de corte transversal, en pacientes con tuberculosis -pulmonar o extrapulmonar- y coinfecci&#xf3;n por HIV, hospitalizados en una instituci&#xf3;n de referencia de Bogot&#xe1; entre el 2019 y el 2021. Resultados. En el grupo de los 102 pacientes con tuberculosis, la prevalencia de infecci&#xf3;n por HIV fue del 52,3% (54). Entre estos 54, 24 pacientes (44,4%) tuvieron confirmaci&#xf3;n microbiol&#xf3;gica o histopatol&#xf3;gica de la tuberculosis y, 19 (35,2 %), infecci&#xf3;n por VIH de novo. En los 54 coinfectados, la mediana de la edad fue de 38 a&#xf1;os (RIC: 29-42). El 79,6 % (43/54) fueron hombres. La mediana del n&#xfa;mero de linfocitos T CD4+ fue de 59 c&#xe9;lulas/&#x3bc;l (RIC: 32-120), y el 72,2 % (39/54) ten&#xed;a menos de 200 c&#xe9;lulas/&#x3bc;l. El 31,4 % (17/54) de los pacientes con antecedente de infecci&#xf3;n por HIV recib&#xed;a terapia antirretroviral. En cuanto a la forma cl&#xed;nica, la tuberculosis fue pulmonar en el 51,9 % (28/54) y extrapulmonar en el 48,1 % (26/54) de los pacientes. La tuberculosis extrapulmonar fue men&#xed;ngea (29,6 %), miliar (12,9 %), pleural (3,7 %) y peritoneal (3,7 %). Hubo 33,3 % de mortalidad intrahospitalaria, asociada con el n&#xfa;mero de linfocitos T CD4+ (p &lt; 0,05), el diagn&#xf3;stico de novo de HIV (p &lt; 0,04) y la presencia de tuberculosis men&#xed;ngea (p &lt; 0,03). Conclusi&#xf3;n. La coinfecci&#xf3;n de Mycobacterium tuberculosis y HIV es frecuente y se relaciona con una inmunosupresi&#xf3;n avanzada, por lo que debe hacerse una b&#xfa;squeda activa de la infecci&#xf3;n con HIV en estos casos. La tuberculosis men&#xed;ngea fue la forma extrapulmonar m&#xe1;s frecuente y se asoci&#xf3; con mortalidad.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puentes-Ariza</LastName><ForeName>Gean Carlo</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0002-7001-1157</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mel&#xe9;ndez-Rhenals</LastName><ForeName>Sugeich</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4593-3125</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia; Servicio de Medicina Interna, Hospital Universitario Nacional de Colombia, Corporaci&#xf3;n Salud UN, Bogot&#xe1;, D.C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nocua-B&#xe1;ez</LastName><ForeName>Laura Cristina</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0003-2869-2339</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe1;ez-Ardila</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4690-9055</Identifier><AffiliationInfo><Affiliation>Servicio de Infectolog&#xed;a, Hospital Sim&#xf3;n Bol&#xed;var, Bogot&#xe1;, D.C., Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prevalencia y caracterizaci&#xf3;n de la coinfecci&#xf3;n por el virus de la inmunodeficiencia humana en pacientes hospitalizados con tuberculosis en un hospital de referencia de Bogot&#xe1;.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Biomedica</MedlineTA><NlmUniqueID>8205605</NlmUniqueID><ISSNLinking>0120-4157</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="eng"><AbstractText Label="INTRODUCTION.">Tuberculosis is the leading cause of death in patients with human immunodeficiency virus infection; tuberculosis-HIV coinfection is highly prevalent.</AbstractText><AbstractText Label="OBJECTIVE.">To establish the prevalence of HIV infection in patients hospitalized with tuberculosis and determine their characteristics and outcomes.</AbstractText><AbstractText Label="MATERIALS AND METHODS.">We conducted a retrospective cross-sectional study in patients diagnosed with pulmonary or extrapulmonary tuberculosis and HIV coinfection, hospitalized in a referral institution in Bogot&#xe1; between 2019 and 2021.</AbstractText><AbstractText Label="RESULTS.">The prevalence of HIV infection in 102 patients with tuberculosis was 52.3% (54/102). Among them, 24 patients (44.4%) had microbiological or histopathological confirmation of tuberculosis infection; and 19 (35.2%) were recently diagnosed with an HIV infection. The median age of the 54 coinfected patients was 38 years (IQR: 29-42); 79.6% (43/54) were men. The median CD4+ T-cell count was 59 cells/&#x3bc;L (IQR: 32-120), and 72.2% (39/54) had a CD4+ count of less than 200 cells/&#x3bc;L; 31.4% (17/54) of patients with a history of HIV infection were receiving antiretroviral therapy. Regarding tuberculosis clinical presentation, 51.9% (28/54) had pulmonary tuberculosis, and 48.1% (26/54) had extrapulmonary tuberculosis. The extrapulmonary tuberculosis forms were meningeal (29.6%), miliary (12.9%), pleural (3.7%), and peritoneal (3.7%). The in-hospital mortality was 33.3%, associated with a low CD4<sup>+</sup> count (p &lt; 0.05), recent HIV diagnosis (p &lt; 0.04), and the presence of meningeal tuberculosis (p &lt; 0.03).</AbstractText><AbstractText Label="CONCLUSION.">The frequency of tuberculosis-HIV coinfection is high and related to an advanced degree of immunosuppression. Therefore, we recommend an active search for coinfection. Meningeal tuberculosis was the most frequent extrapulmonary form and was associated with mortality.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">tuberculosis</Keyword><Keyword MajorTopicYN="N">pulmonary</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">opportunistic</Keyword><Keyword MajorTopicYN="N">infections</Keyword><Keyword MajorTopicYN="N">acquired</Keyword><Keyword MajorTopicYN="N">immunodeficiency</Keyword><Keyword MajorTopicYN="N">syndrome</Keyword></KeywordList><CoiStatement><b>Conflicto de intereses:</b> Los autores declaran no tener conflictos de intereses. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>7</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>20</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>17</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40865109</ArticleId><ArticleId IdType="pmc">PMC12448568</ArticleId><ArticleId IdType="doi">10.7705/biomedica.7664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(1005-70) doi: 10.1016/S0140-6736(14)60844-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60844-8</ArticleId><ArticleId IdType="pmc">PMC4202387</ArticleId><ArticleId IdType="pubmed">25059949</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015;1(15035) doi: 10.1038/nrdp.2015.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.35</ArticleId><ArticleId IdType="pubmed">27188527</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski A, Jansson M, Sk&#xf6;ld M, Rottenberg ME, Kallenius G. Tuberculosis and HIV coinfection. PLoS Pathog. 2012;8(1002464) doi: 10.1371/joumal.ppat.1002464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/joumal.ppat.1002464</ArticleId><ArticleId IdType="pmc">PMC3280977</ArticleId><ArticleId IdType="pubmed">22363214</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)   Global tuberculosis report 2024. Geneva: World Health Organization; 2024.  [18 de febrero de 2025].  Disponible en:  https://iris. who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1
.</Citation></Reference><Reference><Citation>Letang E, Ellis J, Naidoo K, Casas EC, S&#xe1;nchez P, Hassan-Moosa R, et al. Tuberculosis- HIV co-infection: Progress and challenges after two decades of global antiretroviral treatment roll-out. Arch Bronconeumol. 2020;56:446&#x2013;454. doi: 10.1016/j.arbr.2019.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbr.2019.11.013</ArticleId><ArticleId IdType="pubmed">35373756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray JM, Cohn DL. Tuberculosis and HIV coinfection. Semin Respir Crit Care Med. 2013;34:32&#x2013;43. doi: 10.1055/s-0032-1333469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1333469</ArticleId><ArticleId IdType="pubmed">23460004</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge CL, King EJ, Dolan K, McKee M. Prisoners co-infected with tuberculosis and HIV: A systematic review. J Int AIDS Soc. 2016;19:20960&#x2013;20960. doi: 10.7448/IAS.19.1.20960.</Citation><ArticleIdList><ArticleId IdType="doi">10.7448/IAS.19.1.20960</ArticleId><ArticleId IdType="pmc">PMC5112354</ArticleId><ArticleId IdType="pubmed">27852420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis coinfection. Nat Rev Microbiol. 2018;16:80&#x2013;90. doi: 10.1038/nrmicro.2017.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.128</ArticleId><ArticleId IdType="pubmed">29109555</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: A systematic review and meta-analysis. PLoS ONE. 2013;8:e82235. doi: 10.1371/journal.pone.0082235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082235</ArticleId><ArticleId IdType="pmc">PMC3885391</ArticleId><ArticleId IdType="pubmed">24416139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood N, Wilkinson RJ. Understanding and intervening in HIV-associated tuberculosis. Clin Med (Lond) 2015;15(Suppl.6):S43&#x2013;S49. doi: 10.7861/clinmedicine.15-6-s43.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.15-6-s43</ArticleId><ArticleId IdType="pubmed">26634681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadul-P&#xe9;rez S. Protocolo de Vigilancia de Tuberculosis.  [13de junio de 2024];Instituto Nacional de Salud. 2022 :1&#x2013;33. Disponible en:  https://www.ins.gov.co/buscador-eventos/Lineamientos/Pro_Tuberculosis%202022.pdf
.</Citation></Reference><Reference><Citation>Pan American Health Organization  . Factsheet 2022: TB/HIV co-infection in the Americas. Washington D. C.: PAHO/WHO; 2022.  [18 de febrero de 2025].  Disponible en:  https://www.paho.org/sites/default/files/2023-08/2022-cde-factsheet-tb-HIV-americas.pdf
.</Citation></Reference><Reference><Citation>Ministerio de Salud y Protecci&#xf3;n Social  . Lineamiento t&#xe9;cnico operativo del Programa Nacional de Tuberculosis. Direcci&#xf3;n de Promoci&#xf3;n y Prevenci&#xf3;n. Subdirecci&#xf3;n de Enfermedades Transmisibles. Bogot&#xe1;; D.C.: 2020.  [13 de junio de 2024].  Disponible en:  https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%20227%20de%202020.pdf 
.</Citation></Reference><Reference><Citation>StataCorp . Stata Statistical Software: Release 15. College Station. Texas: StataCorp; 2017.</Citation></Reference><Reference><Citation>Ministerio de Salud  . Resoluci&#xf3;n n&#xfa;mero 8430 de 1993 por la cual se establecen las normas cient&#xed;ficas, t&#xe9;cnicas y administrativas para la investigaci&#xf3;n en salud. 1993.  [13 de junio de 2024].  Disponible en:  https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.pdf
.</Citation></Reference><Reference><Citation>Frieden TR, Harold Jaffe DW, Moran JS, Leahy MA, Martinroe JC, Spriggs SR, et al. Revised surveillance case definition for HIV Infection - United States, 2014. Vol. 63. MMWR Recomm Rep; 2014. pp. 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">24717910</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint United Nations Programme on HIV/AIDS (UNAIDS)   In danger: UNAIDS Global AIDS Update 2022. Geneva: UNAIDS; 2022.  [13 de junio de 2024].  Disponible en:  https://www.unaids.org/sites/default/files/media asset/2022-global-aids-update en.pdf
.</Citation></Reference><Reference><Citation>Kawatsu L, Uchimura K, Kaneko N, Imahashi M. Epidemiology of coinfection with tuberculosis and HIV in Japan, 2012-2020. West Pac Surveill Response J. 2022;13:1&#x2013;8. doi: 10.5365/wpsar.2022.13.1.896.</Citation><ArticleIdList><ArticleId IdType="doi">10.5365/wpsar.2022.13.1.896</ArticleId><ArticleId IdType="pmc">PMC9016268</ArticleId><ArticleId IdType="pubmed">35494412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar M, Moshe L, Daniel C, Noa C, Itamar G. HIV prevalence in the Israeli tuberculosis cohort, 1999-2011. BMC Public Health. 2014;14:1090&#x2013;1090. doi: 10.1186/1471-2458-14-1090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-1090</ArticleId><ArticleId IdType="pmc">PMC4221682</ArticleId><ArticleId IdType="pubmed">25335562</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Regional Office for Europe, European Centre for Disease Prevention and Control  . HIV/AIDS surveillance in Europe 2024-2023 data. Copenhagen: WHO Regional Office for Europe; 2024.  [18 de febrero de 2025].  Disponible en:  https://www.ecdc.europa.eu/sites/default/files/documents/HIV_Surveillance_Report_2024.pdf
.</Citation></Reference><Reference><Citation>Cuenta de Alto Costo (CAC)   Situaci&#xf3;n del HIV en Colombia 2024. Bogot&#xe1;, D. C.: Fondo Colombiano de Enfermedades de Alto Costo; 2025.  [18 de febrero de 2025].  Disponible en:  https://cuentadealtocosto.org/publicaciones/situacion-del-HIV-en-colombia-2024/
</Citation></Reference><Reference><Citation>Cort&#xe9;s JA, Hidalgo P, Rey DL, Parra GA, Guti&#xe9;rrez IF. Tuberculosis en pacientes con infecci&#xf3;n por VIH en el Hospital Universitario de San Ignacio, 2002-2006. Infectio. 2007;11:16&#x2013;22.</Citation></Reference><Reference><Citation>Ruiz L, Maya MA, Rueda ZV, L&#xf3;pez L, V&#xe9;lez LA. Current characteristics of tuberculosis and human immunodeficiency virus co-infection in a cohort of hospitalized patients in Medell&#xed;n, Colombia. Biom&#xe9;dica. 2018;38:59&#x2013;67. doi: 10.7705/biomedica.v38i3.3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v38i3.3862</ArticleId><ArticleId IdType="pubmed">30184364</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancredi MV, Sakabe S, Waldman EA. Mortality and survival of tuberculosis coinfected patients living with AIDS in S&#xe3;o Paulo, Brazil: A 12-year cohort study. BMC Infect Dis. 2022;22:223&#x2013;223. doi: 10.1186/s12879-022-07232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07232-6</ArticleId><ArticleId IdType="pmc">PMC8897065</ArticleId><ArticleId IdType="pubmed">35246066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanhueza-Sanzana C, Kerr L, Kendall C. Mortality from AIDS and tuberculosis- HIV coinfection in the Chilean AIDS Cohort of 2000-2017. Cad Sa&#xfa;de P&#xfa;blica. 2021;37:e00212920. doi: 10.1590/0102-311X00212920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0102-311X00212920</ArticleId><ArticleId IdType="pubmed">34190832</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a I, Merch&#xe1;n A, Chaparro PE, L&#xf3;pez LE. Panorama de la coinfecci&#xf3;n tuberculosis/HIV en Bogot&#xe1;, 2001. Biom&#xe9;dica. 2004;24(Supl.1):132&#x2013;137. doi: 10.7705/biomedica.v24iSupp1.1312.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v24iSupp1.1312</ArticleId><ArticleId IdType="pubmed">15495581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mont&#xfa;far Andrade FE, Villa Franco P, Mont&#xfa;far Pantoja MC, Zuleta Tob&#xf3;n JJ, P&#xe9;rez Jaramillo LE, Monsalve Valencia MA, et al. Coinfecci&#xf3;n por virus de inmunodeficiencia humana y micobacterias en un hospital universitario de alta complejidad en Colombia. Infectio. 2016;20:158&#x2013;164. doi: 10.1016/j.infect.2015.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.infect.2015.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint United Nations Programme on HIV/AIDS (UNAIDS)  Global HIV &amp; AIDS statistics - Fact sheet 2024. Geneva: UNAIDS; 2024.  [19 de febrero de 2025].  Disponible en:   https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf 
.</Citation></Reference><Reference><Citation>de Vries G, van de Berg S, van Dam A, Hasanova S, Pareek M, van der Werf MJ, et al. Collaborative tuberculosis/HIV activities in the European Region. ERJ Open Res. 2021;7:00721&#x2013;02020. doi: 10.1183/23120541.00721-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00721-2020</ArticleId><ArticleId IdType="pmc">PMC7836583</ArticleId><ArticleId IdType="pubmed">33532469</ArticleId></ArticleIdList></Reference><Reference><Citation>Abay SM, Deribe K, Reda AA, Biadgilign S, Datiko D, Assefa T, et al. The Effect of early initiation of antiretroviral therapy in TB/HIV-coinfected patients: A systematic review and meta-analysis. J Int Assoc Provid AIDS Care. 2015;14:560&#x2013;570. doi: 10.1177/2325957415599210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2325957415599210</ArticleId><ArticleId IdType="pubmed">26289343</ArticleId></ArticleIdList></Reference><Reference><Citation>Plata-Casas L, Guti&#xe9;rrez-Lesmes O, Herr&#xe1;n-Falla O. Infecci&#xf3;n concomitante por tuberculosis y el virus de la inmunodeficiencia humana: situaci&#xf3;n epidemiol&#xf3;gica en el departamento del Meta, 2010-2015. Biom&#xe9;dica. 2018;38:68&#x2013;79. doi: 10.7705/biomedica.v38i3.3930.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v38i3.3930</ArticleId><ArticleId IdType="pubmed">30184365</ArticleId></ArticleIdList></Reference><Reference><Citation>Rindi L. Rapid molecular diagnosis of extra-pulmonary tuberculosis by Xpert/RIF ultra. Front Microbiol. 2022;13:817661&#x2013;817661. doi: 10.3389/fmicb.2022.817661.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.817661</ArticleId><ArticleId IdType="pmc">PMC9130774</ArticleId><ArticleId IdType="pubmed">35633667</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC. Tuberculous Meningitis International Research Consortium. The current global situation for tuberculous meningitis: Epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res. 2019;4:167&#x2013;167. doi: 10.12688/wellcomeopenres.15535.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15535.1</ArticleId><ArticleId IdType="pmc">PMC7029758</ArticleId><ArticleId IdType="pubmed">32118118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchini D, Ambrosioni J, Brezzo C, Corti M, Rybko A, P&#xe9;rez M, et al. Tuberculous meningitis in HIV-infected and non-infected patients: Comparison of cerebrospinal fluid findings. Int J Tuberc Lung Dis. 2009;13:269&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40391725</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Twenty Years of Disease-Modifying Anti-IBD Drug Use Preceding Colectomy for Refractory IBD-Associated Colitis.</ArticleTitle><Pagination><StartPage>978</StartPage><EndPage>983</EndPage><MedlinePgn>978-983</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003826</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Disease-modifying anti-IBD drugs such as infliximab have altered the treatment of IBD. Despite the increasing availability of disease-modifying anti-IBD drugs, many individuals with IBD still require surgical resection, and the role of disease-modifying anti-IBD drugs in delaying colectomy is limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess use patterns of disease-modifying anti-IBD drug use preceding colectomy for refractory IBD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of institutional data.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Academic tertiary medical center from 2003 to 2022.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with Crohn's disease or ulcerative colitis who underwent total abdominal colectomy or proctocolectomy for medically refractory disease were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Number and type of disease-modifying anti-IBD drugs used before colectomy and use of disease-modifying anti-IBD drugs over time.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 487 patients met inclusion criteria. Most patients had ulcerative colitis (77.8%) and were men (57.1%), with a mean age at diagnosis of 32.1 years. Two hundred eighty patients' first disease-modifying anti-IBD drug was an anti-tumor necrosis factor agent. We found no significant difference in time from diagnosis to colectomy when comparing those who initially received an anti-tumor necrosis factor versus a non-anti-tumor necrosis agent (8.29 vs 8.86 years, p = 0.39). Linear regression demonstrated that, with each decade, patients used about 1.5 additional disease-modifying anti-IBD drugs ( p &lt; 0.01) before surgery. The mean time between diagnosis and colectomy was 8.6 years. Accelerated failure time modeling demonstrated each additional disease-modifying anti-IBD drug was associated with a nonsignificant 5% increase in time between diagnosis and colectomy (1.05 [0.96-1.13], p = 0.25).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Single-center, retrospective.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">During a 20-year period, patients with IBD-associated colitis who ultimately required colectomy received increasing numbers of disease-modifying anti-IBD drugs; however, each additional disease-modifying anti-IBD drug used did not significantly delay time to colectomy, nor did initial non-anti-tumor necrosis factor agent choice. These data suggest that a subset of patients are using increasing numbers of disease-modifying anti-IBD drugs that do not afford them meaningful time in delaying colectomy. See Video Abstract .</AbstractText><AbstractText Label="VEINTE AOS DE USO DE FRMACOS MODIFICADORES DE LA ENFERMEDAD INFLAMATORIA INTESTINAL TRAS UNA COLECTOMA POR COLITIS ASOCIADA A ENFERMEDAD INFLAMATORIA INTESTINAL REFRACTARIA" NlmCategory="UNASSIGNED">ANTECEDENTES:Los medicamentos modificadores de la enfermedad inflamatoria intestinal (DMAID, por sus siglas en ingl&#xe9;s), como el infliximab, han cambiado el tratamiento de la enfermedad inflamatoria intestinal. A pesar de la creciente disponibilidad de estos medicamentos, muchas personas con enfermedad inflamatoria intestinal siguen necesitando una resecci&#xf3;n quir&#xfa;rgica, y el papel de los medicamentos modificadores de la enfermedad inflamatoria intestinal para retrasar la colectom&#xed;a es limitado.OBJETIVO:Evaluar los patrones de uso de los medicamentos modificadores de la enfermedad inflamatoria intestinal antes de la colectom&#xed;a para la enfermedad inflamatoria intestinal refractaria.DISE&#xd1;O:An&#xe1;lisis retrospectivo de datos institucionales.ENTORNO:Centro m&#xe9;dico terciario acad&#xe9;mico entre 2003 y 2022.PACIENTES:Pacientes con enfermedad de Crohn o colitis ulcerosa que se sometieron a una colectom&#xed;a abdominal total o a una proctocolectom&#xed;a por enfermedad m&#xe9;dicamente refractaria.PRINCIPALES MEDIDAS DE RESULTADO:N&#xfa;mero y tipo de medicamentos modificadores de la enfermedad inflamatoria intestinal utilizados antes de la colectom&#xed;a y uso de medicamentos modificadores de la enfermedad inflamatoria intestinal a lo largo del tiempo.RESULTADOS:Un total de 487 pacientes cumplieron los criterios de inclusi&#xf3;n, la mayor&#xed;a de los cuales ten&#xed;an colitis ulcerosa (77,8 %) y eran hombres (57,1 %), con una edad media en el momento del diagn&#xf3;stico de 32,1 a&#xf1;os. El primer medicamento modificador de la enfermedad inflamatoria intestinal que recibieron 280 pacientes fue un agente anti-TNF. No se encontraron diferencias significativas en el tiempo transcurrido desde el diagn&#xf3;stico hasta la colectom&#xed;a al comparar a los que recibieron inicialmente un agente antitumoral necrosis factor frente a un agente no antitumoral necrosis (8,29 a&#xf1;os frente a 8,86 a&#xf1;os, p = 0,39). La regresi&#xf3;n lineal demostr&#xf3; que, con cada d&#xe9;cada, los pacientes utilizaban aproximadamente 1,5 medicamentos modificadores de la enfermedad inflamatoria intestinal adicionales ( p &lt; 0,01) antes de la cirug&#xed;a. El tiempo medio entre el diagn&#xf3;stico y la colectom&#xed;a fue de 8,6 a&#xf1;os. El modelo de tiempo de fracaso acelerado demostr&#xf3; que cada medicamento modificador de la enfermedad inflamatoria intestinal adicional se asociaba con un aumento no significativo del 5 % en el tiempo entre el diagn&#xf3;stico y la colectom&#xed;a (1,05 [0,96-1,13], p = 0,25).LIMITACIONES:Retrospectivo, de un solo centro.CONCLUSIONES:Durante un periodo de 20 a&#xf1;os, los pacientes con colitis asociada a enfermedad inflamatoria intestinal que finalmente requirieron colectom&#xed;a recibieron un n&#xfa;mero cada vez mayor de medicamentos modificadores de la enfermedad inflamatoria intestinal; sin embargo, cada medicamento modificador de la enfermedad inflamatoria intestinal adicional utilizado no retras&#xf3; significativamente el tiempo hasta la colectom&#xed;a, ni tampoco lo hizo la elecci&#xf3;n inicial de un agente no anti-TNF. Estos datos sugieren que un subgrupo de pacientes est&#xe1; utilizando un n&#xfa;mero cada vez mayor de medicamentos modificadores de la enfermedad inflamatoria intestinal que no les proporcionan un tiempo significativo para retrasar la colectom&#xed;a. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ziegler</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2348-6683</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soderman</LastName><ForeName>Caroline J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Penn State College of Medicine, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Alicia C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coates</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koltun</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulaylat</LastName><ForeName>Audrey S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0001-6070-6791</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005765" MajorTopicYN="Y">Gastrointestinal Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-IBD medications</Keyword><Keyword MajorTopicYN="N">Biologics</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Disease-modifying anti-IBD drugs</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>17</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>7</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40391725</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003826</ArticleId><ArticleId IdType="pii">00003453-202508000-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn&#x2019;s disease: medical treatment. J Crohns Colitis. 2020;14:4&#x2013;22.</Citation></Reference><Reference><Citation>Agrawal M, Jess T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United Europ Gastroenterol J. 2022;10:1113&#x2013;1120.</Citation></Reference><Reference><Citation>Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450&#x2013;1461.</Citation></Reference><Reference><Citation>Sandborn WJ, Feagan BG, Rutgeerts P, et al.; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn&#x2019;s disease. N Engl J Med. 2013;369:711&#x2013;721.</Citation></Reference><Reference><Citation>Feagan BG, Sandborn WJ, Gasink C, et al.; UNITI&#x2013;IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn&#x2019;s disease. N Engl J Med. 2016;375:1946&#x2013;1960.</Citation></Reference><Reference><Citation>Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023;330:951&#x2013;965.</Citation></Reference><Reference><Citation>Kobayashi T, Hibi T. Improving IBD outcomes in the era of many treatment options. Nat Rev Gastroenterol Hepatol. 2023;20:79&#x2013;80.</Citation></Reference><Reference><Citation>Devaraj B, Kaiser AM. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis. 2015;21:208&#x2013;220.</Citation></Reference><Reference><Citation>Chapman TP, Satsangi J. Head-to-head biologic therapy in Crohn&#x2019;s disease. Lancet. 2022;399:2169&#x2013;2171.</Citation></Reference><Reference><Citation>Meserve J, Barsky M, Dulai PS. In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn&#x2019;s disease. Best Pract Res Clin Gastroenterol. 2019;38-39:101619.</Citation></Reference><Reference><Citation>Sands BE, Irving PM, Hoops T, et al.; SEAVUE Study Group. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn&#x2019;s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399:2200&#x2013;2211.</Citation></Reference><Reference><Citation>Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965&#x2013;990.</Citation></Reference><Reference><Citation>Khoudari G, Mansoor E, Click B, et al. Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study. Clin Gastroenterol Hepatol. 2022;20:e974&#x2013;e983.</Citation></Reference><Reference><Citation>Bednarz W, Czopnik P, Wojtczak B, Olewi&#x144;ski R, Domos&#x142;awski P, Spodzieja J. Analysis of results of surgical treatment in Crohn&#x2019;s disease. Hepatogastroenterology. 2008;55:998&#x2013;1001.</Citation></Reference><Reference><Citation>Mankarious MM, Greene AC, Schaefer EW, et al. Is the writing on the wall? The relationship between the number of disease-modifying anti-inflammatory bowel disease drugs used and the risk of surgical resection. J Gastrointest Surg. 2024;28:836&#x2013;842.</Citation></Reference><Reference><Citation>Cohen BL, Fleshner P, Kane SV, et al. Prospective cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery. Gastroenterology. 2022;163:204&#x2013;221.</Citation></Reference><Reference><Citation>Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis. 2013;7:853&#x2013;867.</Citation></Reference><Reference><Citation>Zhu Z, Gao Z, Li K. Controversy of preoperative exposure to tumor necrosis factor inhibitors in surgical and infectious complications of inflammatory bowel disease. Gastroenterology. 2023;164:307&#x2013;308.</Citation></Reference><Reference><Citation>Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167&#x2013;182.</Citation></Reference><Reference><Citation>Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21:1847&#x2013;1853.</Citation></Reference><Reference><Citation>Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769&#x2013;779.</Citation></Reference><Reference><Citation>Moroi R, Shiga H, Endo K, et al. Long-term prognosis of Japanese patients with Crohn&#x2019;s disease treated by switching anti-tumor necrosis factor-&#x3b1; antibodies. Inflamm Intest Dis. 2020;5:11&#x2013;19.</Citation></Reference><Reference><Citation>Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:1896&#x2013;1905.</Citation></Reference><Reference><Citation>Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn&#x2019;s disease? Ann Gastroenterol. 2018;31:413&#x2013;424.</Citation></Reference><Reference><Citation>Buisson A, Blanco L, Manlay L, et al. Top-down versus step-up strategies to prevent postoperative recurrence in Crohn&#x2019;s disease. Inflamm Bowel Dis. 2023;29:185&#x2013;194.</Citation></Reference><Reference><Citation>Shergill AK, Terdiman JP. Controversies in the treatment of Crohn&#x2019;s disease: the case for an accelerated step-up treatment approach. World J Gastroenterol. 2008;14:2670&#x2013;2677.</Citation></Reference><Reference><Citation>Danielsen AK. Life after stoma creation. Dan Med J. 2013;60:B4732.</Citation></Reference><Reference><Citation>Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut. 2012;61:459&#x2013;465.</Citation></Reference><Reference><Citation>Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn&#x2019;s disease. Aliment Pharmacol Ther. 2014;39:1349&#x2013;1362.</Citation></Reference><Reference><Citation>Barr&#xe9; A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:896&#x2013;905.</Citation></Reference><Reference><Citation>Stevens TW, Matheeuwsen M, L&#xf6;nnkvist MH, et al. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease&#x2014;personalised medicine in its infancy. Aliment Pharmacol Ther. 2018;48:1213&#x2013;1231.</Citation></Reference><Reference><Citation>Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2020;14:694&#x2013;709.</Citation></Reference><Reference><Citation>Bek S, Nielsen JV, Bojesen AB, et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44:554&#x2013;567.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40192136</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Controlling Oligopolyposis With Colonoscopy: A Cohort Study.</ArticleTitle><Pagination><StartPage>907</StartPage><EndPage>912</EndPage><MedlinePgn>907-912</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003763</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oligopolyposis is defined as between 10 and 100 polyps in the large intestine. If the polyps are adenomas, at least 15% of affected patients will have a syndrome of hereditary colorectal cancer predisposition. Management is aimed at preventing the development of cancer, and options include chemoprevention, colectomy, and colonoscopy, with colectomy generally favored. The role of colonoscopy is relatively unexplored.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present the results of colonoscopic control of patients with oligopolyposis.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective study of a cohort of patients with oligopolyposis separated by genotype and histology.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Hereditary colorectal cancer center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Those with oligopolyposis preferring management with sequential colonoscopy to colectomy and who underwent at least 3 years of follow-up were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Colonoscopy, polypectomy, and surgical resection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Number of colonoscopies, complications of colonoscopies, length of follow-up, number of polyps at first and last colonoscopy, size of the largest polyp at first and last colonoscopy, incidence and stage of cancer, and timing of the cancer diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 59 patients: 29 with sessile serrated polyposis, 13 with MUTYH -associated polyposis, 8 with attenuated familial adenomatous polyposis, and 9 with oligopolyposis not otherwise specified. Patients with familial adenomatous polyposis were 20 years younger than those in the other groups. Patients averaged 1 colonoscopy per year for a mean follow-up between 5 and 11 years. One patient had a post-polypectomy hemorrhage, but there was no perforation and no admission. No patient needed surgery to control benign polyposis. Nine patients had cancer, 6 diagnosed and resected before the start of the colonoscopic surveillance. Three patients with sessile serrated polyposis developed interval cancers while on surveillance, all stage 1. These 3 patients were the only ones who needed colectomy.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Relatively low numbers of familial adenomatous polyposis and oligopolyposis patients. Lack of specific data on variants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In compliant patients and experienced hands, endoscopic control of oligopolyposis can be safe and effective. See Video Abstract .</AbstractText><AbstractText Label="CONTROLANDO LA OLIGOPOLIPOSIS MEDIANTE COLONOSCOPIA UN ESTUDIO DE COHORTE" NlmCategory="UNASSIGNED">ANTECEDENTES:La oligopoliposis se define como la presencia de entre 10 y 100 p&#xf3;lipos en el intestino grueso. En el caso que se trataran de adenomas, al menos el 15% de los pacientes afectados presentar&#xe1; una predisposici&#xf3;n al s&#xed;ndrome hereditario de c&#xe1;ncer colorrectal. El tratamiento se centra en prevenir el desarrollo del c&#xe1;ncer y las opciones incluyen quimioprevenci&#xf3;n, colectom&#xed;a y colonoscopia, siendo la colectom&#xed;a la que generalmente se prefiere. El papel de la colonoscopia es relativamente inexplorado.OBJETIVO:Presentar los resultados del control colonosc&#xf3;pico de pacientes con oligopoliposis.DISE&#xd1;O:Estudio retrospectivo de una cohorte de pacientes con oligopoliposis, separados por genotipo e histolog&#xed;a.ESCENARIO:Centro de c&#xe1;ncer colorrectal hereditario.PACIENTES:Pacientes con oligopoliposis que prefirieron el tratamiento con colonoscopia secuencial a la colectom&#xed;a, y que se sometieron a al menos tres a&#xf1;os de seguimiento.INTERVENCIONES:Colonoscopia y polipectom&#xed;a, resecci&#xf3;n quir&#xfa;rgica.PRINCIPALES MEDIDAS DE RESULTADOS:N&#xfa;mero de colonoscopias, complicaciones de las colonoscopias, duraci&#xf3;n del seguimiento, n&#xfa;mero de p&#xf3;lipos en la primera y &#xfa;ltima colonoscopia, tama&#xf1;o del p&#xf3;lipo m&#xe1;s grande en la primera y &#xfa;ltima colonoscopia, incidencia y estadio del c&#xe1;ncer, y momento del diagn&#xf3;stico.RESULTADOS:Se incluyeron 59 pacientes: 29 con poliposis serrada s&#xe9;sil, 13 con poliposis asociada a MUTYH, 8 con poliposis adenomatosa familiar (PAF) atenuada y 9 con oligopoliposis no especificada. Los pacientes con PAF eran 20 a&#xf1;os m&#xe1;s j&#xf3;venes que los dem&#xe1;s grupos. Los pacientes promediaron una colonoscopia al a&#xf1;o durante una media de seguimiento de entre 5 y 11 a&#xf1;os. Un paciente sufri&#xf3; una hemorragia pospolipectom&#xed;a, pero no se produjo ninguna perforaci&#xf3;n ni ingreso hospitalario. Ning&#xfa;n paciente requiri&#xf3; cirug&#xed;a para controlar la poliposis benigna. Nueve pacientes presentaron c&#xe1;ncer, 6 de ellos diagnosticados y resecados antes del inicio de la vigilancia colonosc&#xf3;pica. Tres pacientes con poliposis serrada s&#xe9;sil desarrollaron c&#xe1;nceres de intervalo durante la vigilancia, todos en estadio 1. Estos fueron los &#xfa;nicos pacientes que necesitaron colectom&#xed;a.LIMITACIONES:N&#xfa;mero relativamente bajo de pacientes con PAF y oligopoliposis. Falta de datos espec&#xed;ficos sobre variantes.CONCLUSIONES:En pacientes cumplidores y con experiencia, el control endosc&#xf3;pico de la oligopoliposis puede ser seguro y eficaz. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Church</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3489-4140</Identifier><AffiliationInfo><Affiliation>Global Center for Integrated Colorectal Surgery and IBD Interventional Endoscopy, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003113" MajorTopicYN="Y">Colonoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003111" MajorTopicYN="Y">Colonic Polyps</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011125" MajorTopicYN="Y">Adenomatous Polyposis Coli</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000236" MajorTopicYN="Y">Adenoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colonoscopy</Keyword><Keyword MajorTopicYN="N">Familial adenomatous polyposis</Keyword><Keyword MajorTopicYN="N">MUTYH-associated polyposis</Keyword><Keyword MajorTopicYN="N">Oligopolyposis</Keyword><Keyword MajorTopicYN="N">Serrated polyposis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>12</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40192136</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003763</ArticleId><ArticleId IdType="pii">00003453-202507000-00017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308:485&#x2013;492.</Citation></Reference><Reference><Citation>Valle L, Monahan KJ. Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management. Lancet Gastroenterol Hepatol. 2024;9:68&#x2013;82.</Citation></Reference><Reference><Citation>Dekker E, Bleijenberg A, Balaguer F; Dutch-Spanish-British Serrated Polyposis Syndrome collaboration. Update on the World Health Organization criteria for diagnosis of serrated polyposis syndrome. Gastroenterology. 2020;158:1520&#x2013;1523.</Citation></Reference><Reference><Citation>Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223&#x2013;262; quiz 263.</Citation></Reference><Reference><Citation>Ishikawa H, Mutoh M, Iwama T, et al. Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy. 2016;48:51&#x2013;55.</Citation></Reference><Reference><Citation>Murano T, Ikematsu H, Shinmura K, et al. Endoscopic management of familial adenomatous polyposis targeting colorectal lesions greater than 5&#x2009;mm in size: a single-center retrospective study. Fam Cancer. 2023;22:83&#x2013;89.</Citation></Reference><Reference><Citation>Valent&#xed;n F, Guarinos C, Ju&#xe1;rez M, et al. Endoscopic surveillance in patients with multiple (10-100) colorectal polyps. Endoscopy. 2016;48:56&#x2013;61.</Citation></Reference><Reference><Citation>Abbass MA, Leach B, Church JM. The second allele: a key to understanding the timing of sporadic and hereditary colorectal tumorigenesis. Genes. 2021;12:1515.</Citation></Reference><Reference><Citation>Liang J, Kalady MF, Church J. Snaring large, serrated polyps. Surg Endosc. 2013;27:1622&#x2013;1627.</Citation></Reference><Reference><Citation>Knudsen AL, Bisgaard ML, B&#xfc;low S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer. 2003;2:43&#x2013;55.</Citation></Reference><Reference><Citation>Kaz AM, Dominitz JA. Can individuals with colonic polyposis be managed safely with colonoscopic surveillance? Endoscopy. 2016;48:7&#x2013;8.</Citation></Reference><Reference><Citation>Church J, Erkan A. Scope or scalpel? A matched study of the treatment of large colorectal polyps. ANZ J Surg. 2018;88:177&#x2013;181.</Citation></Reference><Reference><Citation>Urso EDL, Celotto F, Giandomenico F, et al. Analysis of morbidity and mortality, quality of life and bowel function after total colectomy with ileorectal anastomosis versus right and left hemicolectomy: a study to optimise the treatment of Lynch syndrome and attenuated polyposis coli. Eur J Surg Oncol. 2020;46:1613&#x2013;1619.</Citation></Reference><Reference><Citation>Duclos J, Lefevre JH, Lefran&#xe7;ois M, et al. Immediate outcome, long-term function and quality of life after extended colectomy with ileorectal or ileosigmoid anastomosis. Colorectal Dis. 2014;16:O288&#x2013;O296.</Citation></Reference><Reference><Citation>Church J. Being a colonoscopist. Dis Colon Rectum. 2023;66:1294&#x2013;1296.</Citation></Reference><Reference><Citation>Heald B, Hampel H, Church J, et al.; Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer. 2020;19:223&#x2013;239.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39977207</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1606-7916</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>2 (mar-abr)</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Salud publica de Mexico</Title><ISOAbbreviation>Salud Publica Mex</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>163</StartPage><EndPage>171</EndPage><MedlinePgn>163-171</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21149/15988</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Dar cuenta de la influencia del apoyo social (estructural y funcional) y de aspectos socioecon&#xf3;micos e individuales sobre la inseguridad alimentaria en personas mayores de zonas urbanas de Argentina. Material y m&#xe9;todos. Se desarroll&#xf3; un dise&#xf1;o descriptivo-explicativo y se utilizaron los datos de entrevistados de 60 a&#xf1;os o m&#xe1;s, provenientes de la Encuesta de la Deuda Social Argentina, recolectados en 2019 (n= 1 357) y 2021 (n= 1 289). Se realizaron an&#xe1;lisis descriptivos y se propuso un modelo de regresi&#xf3;n log&#xed;stica binaria.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Los hallazgos muestran la incidencia negativa de factores socioecon&#xf3;micos e individuales; se destaca la pobreza por ingresos (RM= 4.27; IC95%: 2.83,6.43) y el residir en un hogar compuesto por distintas generaciones (RM= 1.48; IC95%: 1.02,2.14). Contar con una red social es un factor protector ante las carencias alimentarias (RM= 2.04; IC95%: 1.53,2.71). La pobreza por ingresos y la falta de apoyo social afectivo son los factores que, en interacci&#xf3;n, indican mayor probabilidad de experimentar inseguridad alimentaria (RM= 3.14; IC95%: 1.22,8.06). Conclusi&#xf3;n. A partir de estos hallazgos se busca contribuir a la discusi&#xf3;n sobre la vinculaci&#xf3;n entre la privaci&#xf3;n alimentaria en personas mayores y aspectos tanto econ&#xf3;micos como psicosociales. Estos hallazgos aportan a diagn&#xf3;sticos que consideren la complejidad del d&#xe9;ficit alimentario en personas mayores.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garofalo</LastName><ForeName>Carolina Sof&#xed;a</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Observatorio de la Deuda Social Argentina, Pontificia Universidad Cat&#xf3;lica Argentina. Buenos Aires, Argentina. Consejo Nacional de Investigaciones Cient&#xed;ficas y T&#xe9;cnicas. Argentina.. carolinasgarofalo@uca.edu.ar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonfiglio</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Observatorio de la Deuda Social Argentina, Pontificia Universidad Cat&#xf3;lica Argentina. Buenos Aires, Argentina.. Juan_bonfiglio@uca.edu.ar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez Esp&#xed;nola</LastName><ForeName>Solange</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Observatorio de la Deuda Social Argentina, Pontificia Universidad Cat&#xf3;lica Argentina. Buenos Aires, Argentina.. Solange_respinola@uca.edu.ar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Apoyo social y desigualdades socioecon&#xf3;micas asociadas con inseguridad alimentaria en la vejez.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Salud Publica Mex</MedlineTA><NlmUniqueID>0404371</NlmUniqueID><ISSNLinking>0036-3634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000084884" MajorTopicYN="Y">Food Insecurity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="Y">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="Y">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N" Type="Geographic">Argentina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011203" MajorTopicYN="N">Poverty</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39977207</ArticleId><ArticleId IdType="doi">10.21149/15988</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39527827</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Is Early, Postinduction Restaging of Rectal Cancer Undergoing Total Neoadjuvant Therapy Associated With Ultimate Treatment Response?</ArticleTitle><Pagination><StartPage>190</StartPage><EndPage>198</EndPage><MedlinePgn>190-198</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003485</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Among patients with rectal cancer treated with total neoadjuvant therapy, it is unclear whether early, postinduction restaging is associated with final tumor response. If so, interim restaging may alter rectal cancer decision-making.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether postinduction restaging with endoscopy and MRI is associated with final tumor response.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">US tertiary care institution accredited by the National Accreditation Program for Rectal Cancer.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with biopsy-proven rectal cancer who underwent total neoadjuvant therapy with interim (postinduction) restaging.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Association between response assessment on postinduction restaging and final treatment response.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred seven patients were analyzed. Patients with postinduction magnetic resonance tumor response grade 1 and 2 or complete endoscopic response were significantly more likely (OR 5.4, p &lt; 0.01 and OR 3.7, p = 0.03, respectively) to ultimately achieve a final complete response. Likewise, the odds of a final incomplete response were significantly higher for patients with postinduction composite partial (OR 4.1, p &lt; 0.01) or minimal (OR 12.0, p &lt; 0.01) responses.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective analysis and lack of detailed subclassification of partial endoscopic response may have limited the conclusions of these data. The limited sample size may also have biased these conclusions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tumor response to induction therapy is associated with the ultimate treatment response to total neoadjuvant therapy among complete or minimal responders; the significance of a partial interim response remains unclear. See Video Abstract .</AbstractText><AbstractText Label="EST ASOCIADA LA REESTADIFICACIN TEMPRANA POSTINDUCCIN DEL CANCER DE RECTO SOMETIDO A TERAPIA NEOADYUVANTE TOTAL CON LA RESPUESTA TERAPUTICA FINAL" NlmCategory="UNASSIGNED">ANTECEDENTES:Entre los pacientes con c&#xe1;ncer de recto tratados con terapia neoadyuvante total, no est&#xe1; claro si la re-estadificaci&#xf3;n temprana posterior a la inducci&#xf3;n est&#xe1; asociada con la respuesta tumoral final. De ser as&#xed;, la re-estadificaci&#xf3;n provisoria podr&#xed;a alterar la toma de decisiones sobre el c&#xe1;ncer rectal.OBJETIVO:Determinar si la re-estadificaci&#xf3;n posterior a la inducci&#xf3;n con endoscopia y resonancia magn&#xe9;tica est&#xe1;n asociadas con la respuesta tumoral final.DISE&#xd1;O:Estudio de cohorte retrospectivoESCENARIO:Instituci&#xf3;n de atenci&#xf3;n terciaria de Estados Unidos, certificada por el Programa Nacional de Acreditaci&#xf3;n para el C&#xe1;ncer de Recto.PACIENTES:Pacientes con c&#xe1;ncer rectal confirmado por biopsia que fueron sometidos a terapia neoadyuvante total con re-estadificaci&#xf3;n provisoria (posterior a la inducci&#xf3;n).PRINCIPALES MEDIDAS DE RESULTADOS:La asociaci&#xf3;n entre la evaluaci&#xf3;n de la respuesta en la re-estadificaci&#xf3;n posterior a la inducci&#xf3;n y la respuesta al final del tratamiento.RESULTADOS:Se estudiaron 107 pacientes. Aquellos que presentaban respuesta tumoral a la resonancia magn&#xe9;tica post-inducci&#xf3;n grado 1-2 o respuesta endosc&#xf3;pica completa tuvieron significativamente m&#xe1;s probabilidades (OR (odds ratio) 5,4 [ p &lt; 0,01] y OR: 3,7 [ p = 0,03], respectivamente) de lograr finalmente una respuesta completa final. Asimismo, las probabilidades de una respuesta incompleta final fueron significativamente mayores para los pacientes con respuestas parciales compuestas post-inducci&#xf3;n (OR: 4,1, p &lt; 0,01) o m&#xed;nimas (OR: 12,0, p &lt; 0,01).LIMITACIONES:El an&#xe1;lisis retrospectivo y la falta de una subclasificaci&#xf3;n detallada de la respuesta endosc&#xf3;pica parcial pueden haber limitado las conclusiones de estos datos. El tama&#xf1;o limitado de la muestra tambi&#xe9;n puede haber sesgado las conclusiones mencionadas.CONCLUSI&#xd3;N:La respuesta tumoral a la terapia de inducci&#xf3;n est&#xe1; asociada con la respuesta final al tratamiento con terapia neoadyuvante total entre los respondedores completos o m&#xed;nimos; la importancia de una respuesta parcial provisional sigue sin estar clara. (Traducci&#xf3;n-Dr. Xavier Delgadillo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorgun</LastName><ForeName>Emre</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>Sumeyye</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommovilla</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanters</LastName><ForeName>Arielle E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purysko</LastName><ForeName>Andrei S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Cleveland Clinic Imaging Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorana</LastName><ForeName>Alok A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Cleveland Clinic Imaging Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnamurthi</LastName><ForeName>Smitha S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amarnath</LastName><ForeName>Sudha R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessler</LastName><ForeName>Hermann</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liska</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, The Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>11</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39527827</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003485</ArticleId><ArticleId IdType="pii">00003453-990000000-00792</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711&#x2013;717.</Citation></Reference><Reference><Citation>Bahadoer RR, Dijkstra EA, van Etten B, et al.; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29&#x2013;42.</Citation></Reference><Reference><Citation>Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546&#x2013;2556.</Citation></Reference><Reference><Citation>Maas M, Lambregts DM, Nelemans PJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol. 2015;22:3873&#x2013;3880.</Citation></Reference><Reference><Citation>Jankowski M, Wysocki WM, Las-Jankowska M, et al. Efficacy of endoscopic surveillance in the detection of local recurrence after radical rectal cancer surgery is limited? A retrospective study. World J Surg Oncol. 2021;19:308.</Citation></Reference><Reference><Citation>Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53:1692&#x2013;1698.</Citation></Reference><Reference><Citation>Dizdarevic E, Hansen TF, Jakobsen A. The prognostic importance of ctDNA in rectal cancer: a critical reappraisal. Cancers (Basel). 2022;14:2252.</Citation></Reference><Reference><Citation>Chakrabarti S, Cohen S, Tin A, et al. Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery. J Clin Oncol. 2024;42(suppl 3):212.</Citation></Reference><Reference><Citation>Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501&#x2013;513.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:1139&#x2013;1167.</Citation></Reference><Reference><Citation>Santiago I, Rodrigues B, Barata M, et al. Re-staging and follow-up of rectal cancer patients with MR imaging when &#x201c;watch-and-wait&#x201d; is an option: a practical guide. Insights Imaging. 2021;12:114.</Citation></Reference><Reference><Citation>Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29:3753&#x2013;3760.</Citation></Reference><Reference><Citation>Trakarnsanga A, Gonen M, Shia J, et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J Natl Cancer Inst. 2014;106:dju248.</Citation></Reference><Reference><Citation>Otto E, Culakova E, Meng S, et al. Overview of Sankey flow diagrams: focusing on symptom trajectories in older adults with advanced cancer. J Geriatr Oncol. 2022;13:742&#x2013;746.</Citation></Reference><Reference><Citation>Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4:e180071.</Citation></Reference><Reference><Citation>Chapman WC, Kim H, Bauer P, et al. Total neoadjuvant therapy with short-course radiation: US experience of a neoadjuvant rectal cancer therapy. Dis Colon Rectum. 2022;65:198&#x2013;206.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Chow OS, Smith DD, et al.; Timing of Rectal Cancer Response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957&#x2013;966.</Citation></Reference><Reference><Citation>Fokas E, Allg&#xe4;uer M, Polat B, et al.; German Rectal Cancer Study Group. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37:3212&#x2013;3222.</Citation></Reference><Reference><Citation>Jimenez L, Perez RO, S&#xe3;o Juli&#xe3;o GP, et al. Prediction of poor response to neoadjuvant chemoradiation in patients with rectal cancer using a DNA repair deregulation score: picking the losers instead of the winners. Dis Colon Rectum. 2020;63:300&#x2013;309.</Citation></Reference><Reference><Citation>Kamran SC, Lennerz JK, Margolis CA, et al. Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer. Clin Cancer Res. 2019;25:5561&#x2013;5571.</Citation></Reference><Reference><Citation>Stockton JD, Tee L, Whalley C, et al.; S-CORT Consortium. Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden. Radiat Oncol. 2021;16:129.</Citation></Reference><Reference><Citation>Akiyoshi T, Tanaka N, Kiyotani K, et al. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019;106:1381&#x2013;1392.</Citation></Reference><Reference><Citation>De Pas T, Pelosi G, de Braud F, et al. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol. 2004;22:4966&#x2013;4970.</Citation></Reference><Reference><Citation>Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer. 2006;94:363&#x2013;371.</Citation></Reference><Reference><Citation>Han KS, Sohn DK, Kim DY, et al. Endoscopic criteria for evaluating tumor stage after preoperative chemoradiation therapy in locally advanced rectal cancer. Cancer Res Treat. 2016;48:567&#x2013;573.</Citation></Reference><Reference><Citation>Fokas E, Appelt A, Glynne-Jones R, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18:805&#x2013;816.</Citation></Reference><Reference><Citation>Perez RO, Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, et al. Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging. Tech Coloproctol. 2014;18:699&#x2013;708.</Citation></Reference><Reference><Citation>Deidda S, Elmore U, Rosati R, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative chemoradiation. JAMA Surg. 2021;156:1141&#x2013;1149.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38498775</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy.</ArticleTitle><Pagination><StartPage>920</StartPage><EndPage>928</EndPage><MedlinePgn>920-928</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003261</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer is associated with improved survival. It is unclear whether residual carcinoma in situ portends a similar outcome.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the survival of patients with locally advanced rectal cancer who received neoadjuvant therapy and achieved pathologic carcinoma in situ versus pathologic complete response.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">National public database.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 4594 patients in the National Cancer Database from 2006 to 2016 with locally advanced rectal cancer who received neoadjuvant therapy, underwent surgery, and had node-negative ypTis or ypT0 on final pathology were included. Of these, 4321 patients (94.1%) had ypT0 and 273 (5.9%) had ypTis on final pathology.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Overall survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age was 60 years, and 1822 patients (39.7%) were women. On initial staging, 54.5% (n&#x2009;=&#x2009;2503) had stage II disease and 45.5% (n&#x2009;=&#x2009;2091) had stage III disease. The ypTis group had decreased overall survival compared to the ypT0 group (HR 1.42; 95% CI, 1.04-1.95; p &#x2009;=&#x2009;0.028). Other factors associated with decreased overall survival were older age at diagnosis, increasing Charlson-Deyo score, and poorly differentiated tumor grade. Variables associated with improved survival were female sex, private insurance, and receipt of both neoadjuvant and adjuvant chemotherapy. For the total cohort, there was no difference in survival between clinical stage II and stage III.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Standard therapy versus total neoadjuvant therapy could not be abstracted. Overall survival was defined as the time from surgery to death from any cause or last contact, allowing for some erroneously misclassified deaths.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ypTis is associated with worse overall survival than ypT0 for patients with locally advanced rectal cancer who receive neoadjuvant chemoradiotherapy followed by surgery. For this cohort, clinical stage was not a significant predictor of survival. Prospective trials comparing survival for these pathologic outcomes are needed. See Video Abstract .</AbstractText><AbstractText Label="SUPERVIVENCIA DEL CNCER DE RECTO PARA EL CARCINOMA RESIDUAL IN SITU VS RESPUESTA PATOLGICA COMPLETA DESPUS DE LA TERAPIA NEOADYUVANTE" NlmCategory="UNASSIGNED">ANTECEDENTESLa respuesta patol&#xf3;gica completa despu&#xe9;s de la quimiorradioterapia neoadyuvante para el c&#xe1;ncer de recto se asocia con una mayor supervivencia. No est&#xe1; claro si el carcinoma residual in situ presagia un resultado similar.OBJETIVOComparar la supervivencia de pacientes con c&#xe1;ncer de recto localmente avanzado que recibieron terapia neoadyuvante y lograron un carcinoma patol&#xf3;gico in situ versus una respuesta patol&#xf3;gica completa.DISE&#xd1;OEstudio de cohorte retrospectivo.ESCENARIOBase de datos p&#xfa;blica nacional.PACIENTESSe incluyeron 4,594 pacientes de la Base de Datos Nacional de C&#xe1;ncer de 2006 a 2016 con c&#xe1;ncer de recto localmente avanzado que recibieron terapia neoadyuvante, fueron sometidos a cirug&#xed;a y tuvieron ganglios negativos, ypTis o ypT0 en el reporte patol&#xf3;gico final. 4.321 (94,1%) tuvieron ypT0 y 273 (5,9%) tuvieron ypTis en el reporte final.PRINCIPALES MEDIDAS DE RESULTADOSupervivencia general.RESULTADOSLa mediana de edad fue de 60 a&#xf1;os. 1.822 pacientes (39,7%) fueron mujeres. El 54,5% (n = 2.503) tuvo la enfermedad en estadio II y el 45,5% (n = 2.091) tuvo la enfermedad en estadio III seg&#xfa;n la estadificaci&#xf3;n inicial. El grupo ypTis tuvo una supervivencia general reducida en comparaci&#xf3;n con el grupo ypT0 (HR 1,42, IC 95 % 1,04-1,95, p = 0,028). Otros factores asociados con una menor supervivencia general fueron una edad m&#xe1;s avanzada al momento del diagn&#xf3;stico, un aumento de la puntuaci&#xf3;n de Charlson-Deyo y un grado tumoral poco diferenciado. Las variables asociadas con una mejor supervivencia fueron el sexo femenino, el seguro privado y la recepci&#xf3;n de quimioterapia neoadyuvante y adyuvante. Para la cohorte total, no hubo diferencias en la supervivencia entre el estadio cl&#xed;nico 2 y el estadio 3.LIMITACIONESNo se pudo resumir el tratamiento est&#xe1;ndar versus el tratamiento neoadyuvante total. La supervivencia general se defini&#xf3; como el tiempo transcurrido desde la cirug&#xed;a hasta la muerte por cualquier causa o &#xfa;ltimo contacto, lo que permite algunas muertes err&#xf3;neamente clasificadas.CONCLUSIONESypTis se asocia con una peor supervivencia general que ypT0 en pacientes con c&#xe1;ncer de recto localmente avanzado que reciben quimiorradioterapia neoadyuvante seguida de cirug&#xed;a. Para esta cohorte, el estadio cl&#xed;nico no fue un predictor significativo de supervivencia. Se necesitan ensayos prospectivos que comparen la supervivencia de estos resultados patol&#xf3;gicos. ( Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohrman</LastName><ForeName>Nathan M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wlodarczyk</LastName><ForeName>Jordan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAndrew</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Algaze</LastName><ForeName>Sandra D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cologne</LastName><ForeName>Kyle G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="Y">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018365" MajorTopicYN="Y">Neoplasm, Residual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095384" MajorTopicYN="N">Pathologic Complete Response</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>18</Day><Hour>15</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38498775</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003261</ArticleId><ArticleId IdType="pii">00003453-202407000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel R, Sandeep Wagle N, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233&#x2013;254.</Citation></Reference><Reference><Citation>Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123:1497&#x2013;1506.</Citation></Reference><Reference><Citation>Iv AA, Koprowski MA, Nabavizadeh N, Tsikitis VL. The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation. Ann Gastroenterol. 2022;35:226&#x2013;233.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines&#xae;) for Rectal Cancer V.3.2023. National Comprehensive Cancer Network, Inc. 2023. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf . Accessed June 1, 2023.</Citation></Reference><Reference><Citation>Bahadoer RR, Dijkstra EA, van Etten B, et al.; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29&#x2013;42.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Chow OS, Smith DD, et al.; Timing of Rectal Cancer Response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957&#x2013;966.</Citation></Reference><Reference><Citation>Conroy T, Bosset J-F, Etienne P-L, et al.; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702&#x2013;715.</Citation></Reference><Reference><Citation>Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40:1681&#x2013;1692.</Citation></Reference><Reference><Citation>Liu S, Jiang T, Xiao L, et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist. 2021;26:e1555&#x2013;e1566.</Citation></Reference><Reference><Citation>Yeo SG, Kim DY, Kim TH, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg. 2010;252:998&#x2013;1004.</Citation></Reference><Reference><Citation>Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835&#x2013;844.</Citation></Reference><Reference><Citation>Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633&#x2013;4640.</Citation></Reference><Reference><Citation>Shin JK, Huh JW, Lee WY, et al. Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer. Sci Rep. 2022;12:7145.</Citation></Reference><Reference><Citation>O&#x2019;Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927&#x2013;1934.</Citation></Reference><Reference><Citation>Fokas E, Schlenska-Lange A, Polat B, et al.; German Rectal Cancer Study Group. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8:e215445.</Citation></Reference><Reference><Citation>Dellas K, H&#xf6;hler T, Reese T, et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol. 2013;8:90.</Citation></Reference><Reference><Citation>Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial&#x2020;. Ann Oncol. 2015;26:1722&#x2013;1728.</Citation></Reference><Reference><Citation>Bujko K, Wyrwicz L, Rutkowski A, et al.; Polish Colorectal Study Group. Long-course oxaliplatin-based preoperative chemoradiation versus 5&#x2009;&#xd7;&#x2009;5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27:834&#x2013;842.</Citation></Reference><Reference><Citation>Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4:e180071.</Citation></Reference><Reference><Citation>Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57&#x2013;64.</Citation></Reference><Reference><Citation>Voss RK, Lin JC, Roper MT, et al. Adjuvant chemotherapy does not improve recurrence-free survival in patients with stage 2 or stage 3 rectal cancer after neoadjuvant chemoradiotherapy and total mesorectal excision. Dis Colon Rectum. 2020;63:427&#x2013;440.</Citation></Reference><Reference><Citation>Paulson EC, Wirtalla C, Armstrong K, Mahmoud NN. Gender influences treatment and survival in colorectal cancer surgery. Dis Colon Rectum. 2009;52:1982&#x2013;1991.</Citation></Reference><Reference><Citation>Shahab D, Gabriel E, Attwood K, et al. Adjuvant chemotherapy is associated with improved overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation. Clin Colorectal Cancer. 2017;16:300&#x2013;307.</Citation></Reference><Reference><Citation>Freischlag K, Sun Z, Adam MA, et al. Association between incomplete neoadjuvant radiotherapy and survival for patients with locally advanced rectal cancer. JAMA Surg. 2017;152:558&#x2013;564.</Citation></Reference><Reference><Citation>Robbins AS, Chen AY, Stewart AK, Staley CA, Virgo KS, Ward EM. Insurance status and survival disparities among nonelderly rectal cancer patients in the National Cancer Data Base. Cancer. 2010;116:4178&#x2013;4186.</Citation></Reference><Reference><Citation>Kozak KR, Moody JS. The impact of T and N stage on long-term survival of rectal cancer patients in the community. J Surg Oncol. 2008;98:161&#x2013;166.</Citation></Reference><Reference><Citation>Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829&#x2013;836.</Citation></Reference><Reference><Citation>Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752&#x2013;76017.</Citation></Reference><Reference><Citation>American Joint Committee on Cancer. Edge SB, Fritz AG, Byrd DR, Greene FL, Compton CC, Trotti III A eds. AJCC Cancer Staging Manual. 8th ed. Chicago, IL: American College of Surgeons; 2017.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546&#x2013;2556.</Citation></Reference><Reference><Citation>Adamo M, Groves C, Dickie L, Ruhl J. SEER Program Coding and Staging Manual 2021. Bethesda, MD: National Cancer Institute; 2020.</Citation></Reference><Reference><Citation>George TJ, Allegra CJ, Yothers G. Neoadjuvant rectal (NAR) score: a new surrogate endpoint in rectal cancer clinical trials. Curr Colorectal Cancer Rep. 2015;11:275&#x2013;280.</Citation></Reference><Reference><Citation>Kim SH, Chang HJ, Kim DY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016;48:998&#x2013;1009.</Citation></Reference><Reference><Citation>Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12(1):19&#x2013;23.</Citation></Reference><Reference><Citation>Mace AG, Pai RK, Stocchi L, Kalady MF. American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer. Dis Colon Rectum. 2015;58:32&#x2013;44.</Citation></Reference><Reference><Citation>Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164&#x2013;172.</Citation></Reference><Reference><Citation>Britten K, McAndrew N. Pathologic complete response as a surrogate endpoint in breast cancer. touchReviews Oncol Haematol. 2021;17:12&#x2013;17.</Citation></Reference><Reference><Citation>Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650&#x2013;2655.</Citation></Reference><Reference><Citation>Zhao Q, Rashid A, Gong Y, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16:29&#x2013;37.</Citation></Reference><Reference><Citation>Chatterjee D, Katz MH, Foo WC, et al. Prognostic significance of new AJCC tumor stage in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy. Am J Surg Pathol. 2017;41:1097&#x2013;1104.</Citation></Reference><Reference><Citation>van Hagen P, Hulshof MC, van Lanschot JJ, et al.; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074&#x2013;2084.</Citation></Reference><Reference><Citation>Conroy T, Etienne P-L, Rio E, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2023;41(suppl):LBA3504&#x2013;LBA3504.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:1139&#x2013;1167.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>